MVA85A

MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG.[1] Phase I clinical trials have been completed[2] and phase II clinical trials are currently underway in South Africa.[3] As of late 2010, those trials, while promising, were not expected to be finished until late 2015, with efficacy trials running in parallel from 2009 to 2019.[4] By contrast, results released in February 2013 were described as "disappointing", showing only a statistically insignificant prevention rate in infants.[5]

References

  1. ↑ McShane H, Pathan AA, Sander CR et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-microbial immunity in humans". Nat Med 10 (11): 1240–44. doi:10.1038/nm1128. PMID 15502839.
  2. ↑ Hawkridge T, Scriba TJ, Gelderbloem et al. (2008). "Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa". J Infect Dis 198 (4): 544–52. doi:10.1086/590185. PMC 2822902. PMID 18582195.
  3. ↑ Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis 6 (8): 522–8. doi:10.1016/S1473-3099(06)70552-7. PMID 16870530.
  4. ↑ McShane H (23 September 2010). "Improving BCG with MVA85A: An update on clinical trials". The Jenner Institute. Retrieved 2 October 2012.
  5. ↑ Walsh, Fergus (4 February 2013). "Tuberculosis vaccine hopes dashed". BBC News. Retrieved 4 February 2013.

External links